GLPG 3067

Drug Profile

GLPG 3067

Alternative Names: ABBV 3067; GLPG-3067; GLPG0367

Latest Information Update: 05 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cystic Fibrosis Foundation Therapeutics; Galapagos NV
  • Developer AbbVie; Galapagos NV
  • Class Antifibrotics; Small molecules
  • Mechanism of Action Cystic fibrosis transmembrane conductance regulator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Cystic fibrosis

Most Recent Events

  • 02 Jan 2018 Galapagos initiates enrolment in a phase I trial for Cystic fibrosis (Combination therapy, In volunteers) in Belgium before January 2018
  • 20 Jun 2017 Galapagos plans a triple combination therapy comprising GLPG 3067, GLPG 2222 and GLPG 2737 for Cystic fibrosis in 2017
  • 20 Jun 2017 Galapagos plans a triple combination therapy comprising GLPG 3067, GLPG 2222 and GLPG 3221 for Cystic fibrosis in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top